# Michele Redell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3600080/publications.pdf

Version: 2024-02-01

| 57 | 1,042 | 516710 16 | 434195 31 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 58 | 58 | 58 | 1878 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood, 2011, 117, 5701-5709. | 1.4 | 198 |
| 2 | Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. Journal of Hematology and Oncology, 2016, 9, 24. | 17.0 | 90 |
| 3 | Targeting Transcription Factors for Cancer Therapy. Current Pharmaceutical Design, 2005, 11, 2873-2887. | 1.9 | 78 |
| 4 | CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Molecular Therapy, 2016, 24, 1615-1626. | 8.2 | 70 |
| 5 | DOT1L Inhibition Sensitizes MLL-Rearranged AML to Chemotherapy. PLoS ONE, 2014, 9, e98270. | 2.5 | 63 |
| 6 | Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance. Blood Advances, 2017, 1, 1387-1397. | 5.2 | 55 |
| 7 | Stat3 Isoforms, Î± and Î², Demonstrate Distinct Intracellular Dynamics with Prolonged Nuclear Retention of Stat3Î² Mapping to Its Unique C-terminal End. Journal of Biological Chemistry, 2007, 282, 34958-34967. | 3.4 | 51 |
| 8 | Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. Pediatric Blood and Cancer, 2019, 66, e27827. | 1.5 | 50 |
| 9 | Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood Advances, 2019, 3, 4215-4227. | 5.2 | 34 |
| 10 | Synthesis, activity and metabolic stability of non-ribose containing inhibitors of histone methyltransferase DOT1L. MedChemComm, 2013, 4, 822. | 3.4 | 31 |
| 11 | Rhodium(II) Proximityâ€Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Antiâ€Leukemia Activity. Angewandte Chemie - International Edition, 2015, 54, 13085-13089. | 13.8 | 31 |
| 12 | FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report. Blood, 2013, 121, 1083-1093. | 1.4 | 29 |
| 13 | Modulating TNFÎ± activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. , 2020, 8, e001229. | | 29 |
| 14 | Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia. Leukemia, 2019, 33, 52-63. | 7.2 | 28 |
| 15 | Stromal <scp>CYR</scp>61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia. British Journal of Haematology, 2015, 170, 704-718. | 2.5 | 27 |
| 16 | Cytogenetically cryptic and FISH-negative PML/RARA rearrangement in acute promyelocytic leukemia detected only by PCR: an exceedingly rare phenomenon. Cancer Genetics, 2014, 207, 48-49. | 0.4 | 25 |
| 17 | Pediatric myeloid sarcoma: a single institution clinicopathologic and molecular analysis. Pediatric Hematology and Oncology, 2020, 37, 76-89. | 0.8 | 20 |
| 18 | Conditional overexpression of Stat3Î± in differentiating myeloid cells results in neutrophil expansion and induces a distinct, antiapoptotic and pro-oncogenic gene expression pattern. Journal of Leukocyte Biology, 2007, 82, 975-985. | 3.3 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Assessing the intracellular fate of rhodium(<scp>ii</scp>) complexes. Chemical Communications, 2016, 52, 11685-11688. | 4.1 | 17 |
| 20 | Intestinal perforation after treatment of Burkitt's lymphoma: Case report and review of the literature. Journal of Pediatric Surgery, 2013, 48, 436-440. | 1.6 | 11 |
| 21 | Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia WithIKZF3Deletion andTP53Mutation. American Journal of Clinical Pathology, 2015, 144, 263-270. | 0.7 | 10 |
| 22 | Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21). Theranostics, 2018, 8, 2189-2201. | 10.0 | 9 |
| 23 | Targeting STAT3 anti-apoptosis pathways with organic and hybrid organicâ€“inorganic inhibitors. Organic and Biomolecular Chemistry, 2020, 18, 3288-3296. | 2.8 | 8 |
| 24 | Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Cancers, 2021, 13, 6263. | 3.7 | 7 |
| 25 | A STAT3 decoy lures AML out of hiding. Blood, 2016, 127, 1628-1629. | 1.4 | 5 |
| 26 | Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia. Clinical and Translational Oncology, 2021, 23, 2141-2154. | 2.4 | 5 |
| 27 | Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells. Blood, 2018, 132, 4246-4246. | 1.4 | 5 |
| 28 | Distinct signaling events promote resistance to mitoxantrone and etoposide in pediatric AML: a Childrenâ€™s Oncology Group report. Oncotarget, 2017, 8, 90037-90049. | 1.8 | 5 |
| 29 | A Novel STAT3 Inhibitor Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia That Incorporate the Stromal Environment. Blood, 2015, 126, 569-569. | 1.4 | 4 |
| 30 | Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica, 2015, 100, e496-e500. | 3.5 | 3 |
| 31 | Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Collaboration. Blood, 2021, 138, 1247-1247. | 1.4 | 3 |
| 32 | IL-10 and TNFÎ± are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a childrenâ€™s oncology group report. Pediatric Hematology and Oncology, 0, , 1-12. | 0.8 | 3 |
| 33 | Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid Leukemia. Blood, 2019, 134, 3912-3912. | 1.4 | 2 |
| 34 | Poorer Relapse-Free Survival in Hispanic Children Diagnosed with Acute Myeloid Leukemia Compared with Non-Hispanics: A Texas Single Institution Experience. Blood, 2015, 126, 1312-1312. | 1.4 | 2 |
| 35 | Targeting Activated Signaling Pathways for the Treatment of IKZF1-Deleted B Lymphoblastic Leukemia. Blood, 2019, 134, 3789-3789. | 1.4 | 2 |
| 36 | FACS Analysis of Stat3/5 Signaling Reveals Ligand Sensitivity As a Significant Prognostic Factor in Pediatric AML: A Children's Oncology Group Report. Blood, 2011, 118, 938-938. | 1.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Multiparameter FACS Analysis of G-CSF and IL-6 Signaling through Stat3 and Stat5 In Primary Pediatric AML Samples.. Blood, 2010, 116, 1051-1051. | 1.4 | 1 |
| 38 | Stroma-Mediated Chemotherapy Resistance in Acute Myeloid Leukemia Cells. Blood, 2011, 118, 242-242. | 1.4 | 1 |
| 39 | Inhibition of BMP-Smad Pathway Reduces Leukemic Stemness in Pediatric AML. Blood, 2019, 134, 3731-3731. | 1.4 | 1 |
| 40 | Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Blood, 2020, 136, 39-40. | 1.4 | 1 |
| 41 | Targeting signaling pathways vulnerabilities for the treatment of IKZF1-deleted ph-negative B lymphoblastic leukemia.. Journal of Clinical Oncology, 2022, 40, 7033-7033. | 1.6 | 1 |
| 42 | Adoptive immunotherapy for AML with CD123-engager T cells. , 2015, 3, . | | 0 |
| 43 | Comparision of four and six color multiparametric flow cytometry panels to diagnose pediatric leukemias. Annals of Global Health, 2018, 82, 440. | 2.0 | 0 |
| 44 | Introduction to the Special Issue on Pediatric Acute Myeloid Leukemia: Current Management and Future Directions. Children, 2021, 8, 698. | 1.5 | 0 |
| 45 | Overexpression of Stat3Î±, but Not StatÎ², in Myeloid Cells Results in Neutrophil Expansion through Reduced Apoptosis and Modulation of a Unique Set of Apoptosis Pathway Genes.. Blood, 2006, 108, 1147-1147. | 1.4 | 0 |
| 46 | Wild-Type and Mutant C-Kit Activation of Stat3Î± Contribute to Leukemogenesis through Distinct Effects on Myeloid Cell Proliferation and Resistance to Apoptosis. Blood, 2008, 112, 5317-5317. | 1.4 | 0 |
| 47 | Stat3Î² Promotes Basal Granulopoiesis and Inhibits Emergency Granulopoiesis, While Stat3Î± Inhibits Basal Granulopoiesis and Promotes Emergency Granulopoiesis. Blood, 2008, 112, 3871-3871. | 1.4 | 0 |
| 48 | Increased Responsiveness to Ligand Stimulation of the STAT Pathway At Relapse in Acute Myelogenous Leukemia. Blood, 2012, 120, 3544-3544. | 1.4 | 0 |
| 49 | Bone Marrow Stromal Cells Enhance DNA Damage Signaling Independent Of Stat3 Activation In Pediatric AML. Blood, 2013, 122, 2548-2548. | 1.4 | 0 |
| 50 | Stromal CYR61 Confers Resistance to Mitoxantrone Via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukemia. Blood, 2014, 124, 2228-2228. | 1.4 | 0 |
| 51 | CD123-Engager T Cells As a Novel Immunotherapeutic for AML. Blood, 2014, 124, 3762-3762. | 1.4 | 0 |
| 52 | Differential Expression of Adhesion Molecule Receptors May Influence Bone Marrow Microenvironment-Mediated Protection of Leukemia-Initiating Cells (LICs) in Infant MLL-rearranged (MLL-R) Acute Lymphoblastic Leukemia (ALL). Blood, 2016, 128, 1585-1585. | 1.4 | 0 |
| 53 | Rapid Infusion of Rituximab Is Well Tolerated in Children with Hematologic, Oncologic, and Rheumatologic Disorders. Blood, 2016, 128, 2329-2329. | 1.4 | 0 |
| 54 | The Bone Marrow Environment Promotes Resistance to Mitoxantrone and Etoposide By Distinct Mechanisms in Pediatric AML. Blood, 2016, 128, 3943-3943. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Interleukin-6 Levels Predict Relapse Free Survival in Pediatric AML and Suggest a Mechanism of Chemotherapy Resistance. Blood, 2016, 128, 1724-1724. | 1.4 | 0 |
| 56 | Signaling Responses to Stroma-Derived Soluble Factors Are Associated with Outcome and with Expression of Microenvironment-Related Genes in Pediatric AML. Blood, 2018, 132, 1510-1510. | 1.4 | 0 |
| 57 | Cite-Seq Reveals Distinct Patterns and Potential Mechanisms of Relapse in Pediatric AML. Blood, 2021, 138, 3458-3458. | 1.4 | 0 |